Allogeneic bone marrow–derived mesenchymal stromal cells for hepatitis B virus–related acute‐on‐chronic liver failure: A randomized controlled trial

• Published in: Hepatology (Baltimore, Md.) Vol. 66; no. 1; pp. 209 - 219
• Main Authors: Lin, Bing‐liang, Chen, Jun‐feng, Qiu, Wei‐hong, Wang, Ke‐wei, Xie, Dong‐ying, Chen, Xiao‐yong, Liu, Qiu‐li, Peng, Liang, Li, Jian‐guo, Mei, Yong‐yu, Weng, Wei‐zhen, Peng, Yan‐wen, Cao, Hui‐juan, Xie, Jun‐qiang, Xie, Shi‐bin, Xiang, Andy Peng, Gao, Zhi‐liang
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.07.2017
• Subjects: Acute-On-Chronic Liver Failure - etiology; Acute-On-Chronic Liver Failure - mortality; Acute-On-Chronic Liver Failure - physiopathology; Acute-On-Chronic Liver Failure - therapy; Adult; Bilirubin; Bone marrow; Cause of Death; China; Confidence intervals; Female; Fever; Hepatitis; Hepatitis B; Hepatitis B - complications; Hepatitis B - physiopathology; Hepatitis B virus - isolation & purification; Hepatology; Humans; Kaplan-Meier Estimate; Liver; Liver failure; Lymphocytes B; Male; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchyme; Middle Aged; Mortality; Prognosis; Prospective Studies; Risk Assessment; Side effects; Statistics, Nonparametric; Stromal cells; Survival; Survival Analysis; Transplantation, Homologous; Treatment Outcome

Mortality from hepatitis B virus (HBV)–related acute‐on‐chronic liver failure (ACLF) is high due to limited treatment options. Preclinical and clinical investigations have proved that treatment with mesenchymal stromal cells (MSCs) is beneficial for recovery from liver injury. We hypothesized that t...